Articles from MKT Capital Ltd.

MKT Capital Ltd. (together with its affiliates, “MKT Capital” or “we”), a significant long-term shareholder of Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (“Aurinia” or the “Company”), today issued the following statement in response to the Company’s announcement that Kevin Tang has been appointed Chief Executive Officer, effective immediately.

MKT Capital Ltd. and Lucien Selce (together with certain of their affiliates, “we”), who collectively own significant equity stakes in Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) ("Aurinia" or the "Company"), today issued the following letter to shareholders.

MKT Capital Ltd. (together with its affiliates, “MKT Capital” or “we”), the beneficial owner of approximately 4.2% of the outstanding common shares of Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (“Aurinia” or the “Company”), today commented on the Company’s decision to initiate a review of strategic alternatives, including a potential value-maximizing sale, following MKT Capital’s successful withhold campaign at the Company’s 2023 Annual General Meeting of Shareholders.

MKT Capital Ltd. (together with its affiliates, “MKT Capital” or “we”), a significant shareholder of Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (“Aurinia” or the “Company”) with beneficial ownership of approximately 4.2% of Aurinia’s outstanding shares, today condemned the Company’s sluggish response to the outcome of its 2023 Annual General Meeting of Shareholders (the “Annual Meeting”) held on May 17, 2023.

MKT Capital Ltd. (together with its affiliates, “MKT Capital” or “we”), a significant shareholder of Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (“Aurinia” or the “Company”) with beneficial ownership of approximately 4.2% of Aurinia’s outstanding shares, today commented on the outcome of the Company’s 2023 Annual General Meeting of Shareholders (the “Annual Meeting”) held on May 17, 2023. At the Annual Meeting, Chairman George Milne and Compensation Committee Chair Joseph Hagan received less than majority support from shareholders and have subsequently submitted their resignations to the Board of Directors (the “Board”), pursuant to the Company’s Majority Voting Policy. Additionally, the Company’s non-binding advisory vote on executive compensation did not receive majority support and the proposed amendment to the equity incentive plan was not approved.

MKT Capital Ltd. (together with its affiliates, “MKT Capital” or “we”) is a significant shareholder of Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (“Aurinia” or the “Company”) with beneficial ownership of approximately 4.2% of Aurinia’s outstanding shares. Today, MKT Capital commented on the filing by the Company’s largest shareholder, Iljin SNT Co., Ltd. (together with its affiliates, “Iljin”), stating its intention to WITHHOLD support for Chairman Dr. George Milne, Compensation Committee Chair Joseph Hagan, David Jayne, Daniel Billen, R. Hector Mackay-Dunn, Jill Leversage and Brinda Balakrishnan at the upcoming Annual General Meeting of Shareholders (the “Annual Meeting”) to be held on May 17, 2023. Yesterday, Iljin filed a letter with the Securities and Exchange Commission that it sent to Aurinia’s Board of Directors (the “Board”) expressing its concerns with the composition of the Company’s Board and declaring its voting intentions.

MKT Capital Ltd. (together with its affiliates, “MKT Capital” or “we”), a significant shareholder of Aurinia Pharmaceuticals, Inc. (NASDAQ: AUPH) (“Aurinia” or the “Company”) with beneficial ownership of approximately 4.2% of Aurinia’s outstanding shares, today issued a statement regarding the Company’s recently issued financial results for the quarter ended March 31, 2023.

MKT Capital Ltd. (together with its affiliates, “MKT Capital” or “we”), a significant shareholder of Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (“Aurinia” or the “Company”) with beneficial ownership of approximately 4.2% of Aurinia’s outstanding shares, today announced that Institutional Shareholder Services Inc. (“ISS”), a leading independent proxy advisory firm, has recommended shareholders vote AGAINST the ratification of the Company’s named executive officers’ (“NEOs”) compensation at the upcoming 2023 Annual General Meeting of Shareholders (the “Annual Meeting”) scheduled to be held on May 17, 2023.

MKT Capital Ltd., a significant shareholder of Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (“Aurinia” or the “Company”) which together with its affiliates beneficially owns approximately 4.2% of Aurinia’s outstanding shares, today issued the following letter to the Company's shareholders.